1. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
- Author
-
Meredith Little, Lisa Brown, José Antonio Sanches, Pietro Quaglino, J. Scarisbrick, Oliver Bechter, Kerry Taylor, David E. Fisher, Matthew Onsum, M. Corinna Palanca-Wessels, Veronica Bunn, Pascal Wolter, Steven M. Horwitz, Jan Walewski, Judith Trotman, Madeleine Duvic, Rudolf Stadler, Lauren C. Pinter-Brown, Herbert Eradat, Reinhard Dummer, Pier Luigi Zinzani, Marise McNeeley, Sean Whittaker, Alejandro A. Gru, Pablo L. Ortiz-Romero, Julie Lisano, H. Miles Prince, Michael Weichenthal, Youn H. Kim, William L. Trepicchio, Oleg E. Akilov, Kim Y.H., Prince H.M., Whittaker S., Horwitz S.M., Duvic M., Bechter O., Sanches J.A., Stadler R., Scarisbrick J., Quaglino P., Zinzani P.L., Wolter P., Eradat H., Pinter-Brown L.C., Ortiz-Romero P.L., Akilov O.E., Trotman J., Taylor K., Weichenthal M., Walewski J., Fisher D., McNeeley M., Gru A.A., Brown L., Palanca-Wessels M.C., Lisano J., Onsum M., Bunn V., Little M., Trepicchio W.L., and Dummer R.
- Subjects
0301 basic medicine ,Oncology ,Male ,Cancer Research ,Lymphoma ,Choice Behavior ,0302 clinical medicine ,Antineoplastic Agents, Immunological ,immune system diseases ,Retrospective Studie ,hemic and lymphatic diseases ,Objective response ,80 and over ,Brentuximab vedotin ,Cancer ,Aged, 80 and over ,Brentuximab Vedotin ,Mycosis Fungoide ,integumentary system ,medicine.diagnostic_test ,Antibody-drug conjugate ,CD30 ,Cutaneous T-cell lymphoma ,Efficacy ,Large-cell transformation ,Mycosis fungoides ,Progression-free survival ,Safety ,Hematology ,Middle Aged ,Prognosis ,Survival Rate ,Immunological ,International Agencie ,030220 oncology & carcinogenesis ,Public Health and Health Services ,Female ,medicine.drug ,Human ,Adult ,medicine.medical_specialty ,Prognosi ,Oncology and Carcinogenesis ,Ki-1 Antigen ,Antineoplastic Agents ,Follow-Up Studie ,Decision Support Techniques ,03 medical and health sciences ,Young Adult ,Rare Diseases ,Clinical Research ,Internal medicine ,Physicians ,Biopsy ,medicine ,Humans ,Oncology & Carcinogenesis ,Retrospective Studies ,Aged ,business.industry ,International Agencies ,medicine.disease ,Clinical trial ,030104 developmental biology ,Orphan Drug ,Physician ,business ,Follow-Up Studies - Abstract
INTRODUCTION: Mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma, can lead to disfiguring lesions, debilitating pruritus and frequent skin infections. This study assessed response to brentuximab vedotin in patients with MF in the phase III ALCANZA study. METHODS: Baseline CD30 levels and large-cell transformation (LCT) status were centrally reviewed in patients with previously-treated CD30-positive MF using ≥2 skin biopsies obtained at screening; eligible patients required ≥1 biopsy with ≥10% CD30 expression. Patients were categorised as CD30min
- Published
- 2021